• Je něco špatně v tomto záznamu ?

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

EM. Ocio, YA. Efebera, R. Hájek, J. Straub, V. Maisnar, JR. Eveillard, L. Karlin, MV. Mateos, A. Oriol, V. Ribrag, PG. Richardson, S. Norin, J. Obermüller, NA. Bakker, L. Pour

. 2024 ; 109 (3) : 867-876. [pub] 20240301

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze I, klinické zkoušky, fáze II, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007008

Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory MM refractory to an immunomodulatory agent and/or a proteasome inhibitor and who had received one to four prior lines of therapy. Primary objectives were to determine the optimal dose of melflufen in triplet combination (phase I) and overall response rate (phase IIa). In total, 33 patients were treated in the daratumumab arm and 23 patients received therapy in the bortezomib arm. No dose-limiting toxicities were reported at either melflufen dose level with either combination. With both triplet regimens, the most common grade ≥3 treatment-emergent adverse events were thrombocytopenia and neutropenia; thrombocytopenia was the most common treatment-emergent adverse event leading to treatment discontinuation. In the daratumumab arm, patients receiving melflufen 30 mg remained on treatment longer than those receiving the 40-mg dose. In the daratumumab arm, the overall response rate was 73% and median progression-free survival was 12.9 months. Notably, in the bortezomib arm, the overall response rate was 78% and median progression-free survival was 14.7 months. Considering the totality of the data, melflufen 30 mg was established as the recommended dose for use with dexamethasone and daratumumab or bortezomib for future studies in relapsed/refractory MM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007008
003      
CZ-PrNML
005      
20240423155643.0
007      
ta
008      
240412s2024 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2023.283490 $2 doi
035    __
$a (PubMed)37646657
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Ocio, Enrique M $u Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander. ocioem@unican.es
245    10
$a ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study / $c EM. Ocio, YA. Efebera, R. Hájek, J. Straub, V. Maisnar, JR. Eveillard, L. Karlin, MV. Mateos, A. Oriol, V. Ribrag, PG. Richardson, S. Norin, J. Obermüller, NA. Bakker, L. Pour
520    9_
$a Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen (30 or 40 mg) and dexamethasone (40 mg with daratumumab; 20 mg followed by 40 mg with bortezomib; dose reduced if aged ≥75 years) in triplet combination with daratumumab (16 mg/kg; daratumumab arm) or bortezomib (1.3 mg/m2; bortezomib arm) in patients with relapsed/refractory MM refractory to an immunomodulatory agent and/or a proteasome inhibitor and who had received one to four prior lines of therapy. Primary objectives were to determine the optimal dose of melflufen in triplet combination (phase I) and overall response rate (phase IIa). In total, 33 patients were treated in the daratumumab arm and 23 patients received therapy in the bortezomib arm. No dose-limiting toxicities were reported at either melflufen dose level with either combination. With both triplet regimens, the most common grade ≥3 treatment-emergent adverse events were thrombocytopenia and neutropenia; thrombocytopenia was the most common treatment-emergent adverse event leading to treatment discontinuation. In the daratumumab arm, patients receiving melflufen 30 mg remained on treatment longer than those receiving the 40-mg dose. In the daratumumab arm, the overall response rate was 73% and median progression-free survival was 12.9 months. Notably, in the bortezomib arm, the overall response rate was 78% and median progression-free survival was 14.7 months. Considering the totality of the data, melflufen 30 mg was established as the recommended dose for use with dexamethasone and daratumumab or bortezomib for future studies in relapsed/refractory MM.
650    _2
$a lidé $7 D006801
650    12
$a monoklonální protilátky $7 D000911
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    12
$a melfalan $x analogy a deriváty $7 D008558
650    12
$a mnohočetný myelom $x diagnóza $x farmakoterapie $7 D009101
650    12
$a nádory plazmocelulární $7 D054219
650    12
$a neutropenie $x chemicky indukované $7 D009503
650    12
$a fenylalanin $x analogy a deriváty $7 D010649
650    12
$a trombocytopenie $7 D013921
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
700    1_
$a Efebera, Yvonne A $u Department of Hematology/Oncology, Division of Blood and Marrow Transplant and Cellular Therapy, OhioHealth, Columbus, OH, USA and OhioHealth, Columbus, OH
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Straub, Jan $u Všeobecná fakultní nemocnice, Prague, Czech Republic
700    1_
$a Maisnar, Vladimir $u Fourth Department of Medicine - Hematology, Charles University Hospital, Hradec Králové, Czech Republic
700    1_
$a Eveillard, Jean-Richard $u Hôpital Morvan, Brest
700    1_
$a Karlin, Lionel $u Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre-Bénite
700    1_
$a Mateos, María-Victoria $u Hospital Clinico Universitario de Salamanca/IBSAL/CIC, Salamanca
700    1_
$a Oriol, Albert $u Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona
700    1_
$a Ribrag, Vincent $u Drug Development Department (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif
700    1_
$a Richardson, Paul G $u Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
700    1_
$a Norin, Stefan $u Oncopeptides AB, Stockholm
700    1_
$a Obermüller, Jakob $u Oncopeptides AB, Stockholm
700    1_
$a Bakker, Nicolaas A $u Oncopeptides AB, Stockholm
700    1_
$a Pour, Luděk $u Fakultní nemocnice Brno, Brno, Czech Republic
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 109, č. 3 (2024), s. 867-876
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37646657 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155639 $b ABA008
999    __
$a ok $b bmc $g 2081170 $s 1216775
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 109 $c 3 $d 867-876 $e 20240301 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

    Možnosti archivace